Fisher Ri
About
In The Last Decade
Fisher Ri
11 papers receiving 216 citations
Peers
Comparison fields: 5 of 59
- Oncology 114
- Pathology and Forensic Medicine 110
- Genetics 42
- Molecular Biology 40
- Neurology 36
Countries citing papers authored by Fisher Ri
This map shows the geographic impact of Fisher Ri's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fisher Ri with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fisher Ri more than expected).
Fields of papers citing papers by Fisher Ri
This network shows the impact of papers produced by Fisher Ri. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fisher Ri. The network helps show where Fisher Ri may publish in the future.
Co-authorship network of co-authors of Fisher Ri
This figure shows the co-authorship network connecting the top 25 collaborators of Fisher Ri. A scholar is included among the top collaborators of Fisher Ri based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fisher Ri. Fisher Ri is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | Relapse after successful treatment with immunotherapy: lessons for the future. | 2 |
| 2 | Clinical trials of alpha-interferon in the treatment of non-Hodgkin's lymphoma. | 12 |
| 3 | CHOP chemotherapy as standard therapy for treatment of patients with diffuse histiocytic lymphoma. | 8 |
| 4 | Phase II trial of chlorozotocin in malignant melanoma, breast cancer, and other solid tumors. | 2 |
| 5 | A prospective randomized study of adjuvant parenteral nutrition in the treatment of diffuse lymphoma: effect on drug tolerance. | 31 |
| 6 | Staging of non-Hodgkin's lymphoma. | 30 |
| 7 | Chemotherapy for murine ovarian cancer: a rationale for ip therapy with adriamycin. | 28 |
| 8 | Phase II study of high-dose methotrexate in patients with advanced malignant melanoma. | 2 |
| 9 | Combination chemotherapy in non-Hodgkin's lymphoma: results of long-term followup. | 88 |
| 10 | Receptors for steroid hormones in human melanoma. | 21 |
| 11 | Natural history of malignant melanoma as related to therapy. | 26 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.